ISM-001 DEVELOPMENT STATUS

IsomAb has developed a strong pre-clinical data package establishing that the mechanism of action works in state-of-the-art animal models that closely approximate human conditions, and is leveraging human biosamples for target validation.

It has a drug candidate in the form of a high affinity and scaleable humanised antibody that can be manufactured at scale and cost-effectively in standard manufacturing facilities.